220 related articles for article (PubMed ID: 30726248)
21. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.
Gonzalez JM; Rodriguez CA; Zuluaga AF; Agudelo M; Vesga O
PLoS One; 2015; 10(11):e0141872. PubMed ID: 26536105
[TBL] [Abstract][Full Text] [Related]
22. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.
Balfour JA; Bryson HM; Brogden RN
Drugs; 1996 Jan; 51(1):99-136. PubMed ID: 8741235
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.
Petersen PJ; Jacobus NV; Weiss WJ; Testa RT
Antimicrob Agents Chemother; 1991 Jan; 35(1):203-7. PubMed ID: 1901698
[TBL] [Abstract][Full Text] [Related]
24. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
Daimon Y
Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059
[TBL] [Abstract][Full Text] [Related]
25.
Powles MA; Galgoci A; Misura A; Colwell L; Dingley KH; Tang W; Wu J; Blizzard T; Motyl M; Young K
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866878
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
27. CW-270033, a novel pyrrolidinyl-thio carbapenem, has potent antimicrobial activity in vitro and in vivo.
Kim J; Ha JR; Oh SW; Kim HG; Lee JM; Lee DG; Lee SH; Kim JG
Biol Pharm Bull; 2007 Mar; 30(3):575-9. PubMed ID: 17329859
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
Bradley JS; Makieieva N; Tøndel C; Roilides E; Kelly MS; Patel M; Vaddady P; Maniar A; Zhang Y; Paschke A; Chen LF
J Clin Pharmacol; 2023 Dec; 63(12):1387-1397. PubMed ID: 37562063
[TBL] [Abstract][Full Text] [Related]
29. Laboratory data which differentiate meropenem and imipenem.
Edwards JR; Turner PJ
Scand J Infect Dis Suppl; 1995; 96():5-10. PubMed ID: 7652504
[TBL] [Abstract][Full Text] [Related]
30. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
31. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
Bhagunde P; Zhang Z; Racine F; Carr D; Wu J; Young K; Rizk ML
Int J Infect Dis; 2019 Dec; 89():55-61. PubMed ID: 31479762
[TBL] [Abstract][Full Text] [Related]
32. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
[TBL] [Abstract][Full Text] [Related]
34. [Imipenem with cilastatin; indications and contraindications].
Loebis LH
Ned Tijdschr Geneeskd; 1992 Mar; 136(13):613-6. PubMed ID: 1557157
[No Abstract] [Full Text] [Related]
35. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
[TBL] [Abstract][Full Text] [Related]
36. Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Antimicrob Agents Chemother; 2015 Jan; 59(1):53-8. PubMed ID: 25313208
[TBL] [Abstract][Full Text] [Related]
37. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.
Zuluaga AF; Agudelo M; Rodriguez CA; Vesga O
BMC Clin Pharmacol; 2009 Jan; 9():1. PubMed ID: 19149891
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
Lomaestro BM; Drusano GL
Antimicrob Agents Chemother; 2005 Jan; 49(1):461-3. PubMed ID: 15616337
[TBL] [Abstract][Full Text] [Related]
39. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects.
Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084
[TBL] [Abstract][Full Text] [Related]
40. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
